Levels of Apelin, Endoglin, and Transforming Growth Factor Beta 1 in Iraqi Women with Polycystic Ovary Syndrome
Polycystic ovary syndrome (PCOS) is one of the most common causes of infertility in women of reproductive age. The aim of the study was to determine the level of apelin, insulin resistance (IR), transforming growth factor beta 1 (TGF-β1), and endoglin in women with polycystic ovary syndrome. Fifty PCOS patients and 40 non-PCOS infertile patients were recruited. The fasting serum levels of folliclestimulating hormone (FSH), luteinizing hormone (LH), testosterone (T), prolactin, fasting blood glucose, insulin, and apelin at the early follicular phase were measured. Levels of apelin, LH, LH/FSH, T, and fasting insulin, as well as homeostatic model assessment of IR (HOMA-IR) in PCOS patients, were significantly higher than in the control group. Correlation analysis showed that apelin level was positively correlated with body mass index and HOMA-IR. Apelin levels and TGF-β1 were significantly increased in PCOS patients while show decrease levels of endoglin.
E. Karimi, A. Moini, M. Yaseri, N. Shirzad, M. Sepidarkish, M. Hossein-Boroujerdi and M. J Hosseinzadeh-Attar. “Effects ofsynbiotic supplementation on metabolic parameters and apelin in women with polycystic ovary syndrome: A randomised doubleblind placebo-controlled trial”. The British Journal of Nutrition, vol. 119, no. 4, pp. 398-406, 2018.
G. Bozdag, S. Mumusoglu, D. Zengin, E. Karabulut and O.B. Yildiz. “The prevalence and phenotypic features of polycystic ovary syndrome: A systematic review and meta-analysis”. Human Reproduction, vol. 31, pp. 2841-2885, 2016.
I. R. Indran, Z. Huang, L.W. Khin, J. K. Y. Chan, V. Viardot-Foucault and E. L. Yong. “Simplified 4-item criteria for polycystic ovary syndrome: A bridge too far”? Clinical Endocrinology (Oxford), vol. 89, no. 2, 202-211, 2018.
X. Z. Zhang, Y. L. Pang, X. Wang and Y. H. Li. “Computational characterization and identification of human polycystic ovary syndrome genes”. Scientific Reports, vol. 8, no. 1, pp. 12949, 2018.
N. Naderpoor, S. Shorakae, A. Joham, J. Boyle, B. De Courten and H. J. Teede. “Obesity and polycystic ovary syndrome”. Minerva Endocrinologica, vol. 15, no. 1, pp. 37-51, 2015.
J. Kataoka, E. C. Tassone, M. Misso, A. E. Joham, E. Stener-Victorin, H. Teede and L. J. Moran. “Weight management interventions in women with and without PCOS: A systematic review”. Nutrients, vol. 9, no. 9, pp. E996, 2017.
M. H. Dahan and G. Reaven. “Relationship among obesity, insulin resistance, and hyperinsulinemia in the polycystic ovary syndrome”. Endocrine, vol. 64, no. 3, pp. 685-689, 2019.
I. Lazúrová, Z. Lazúrová, J. Figurová, S. Ujházi, I. Dravecká, J. Mašlanková and M. Mareková. “Relationship between steroid hormones and metabolic profile in women with polycystic ovary syndrome”. Physiological Research, vol. 68, no. 3, pp. 457-465, 2019.
E. Koivuaho, J. Laru, M. Ojaniemi, K. Puukka, J. Kettunen, J.S. Tapanainen, S. Franks, M. R. Järvelin, L. Morin-Papunen, S. Sebert and T. T. Piltonen. “Age at adiposity rebound in childhood is associated with PCOS diagnosis and obesity in adulthood-longitudinal analysis of BMI data from birth to age 46 in cases of PCOS”. International Journal Obesity (London), vol. 43, no. 7, pp. 1370-1379, 2019.
I. Falcão-PiresI, N. Gonçalves, T. Henriques-Coelho, D. Moreira-Gonçalves, R. Roncon-Albuquerque and A. F. Leite-Moreira.“Apelin decreases myocardial injury and improves right ventricular function in monocrotaline-induced pulmonary hypertension”. American Journal of Physiology Heart and Circulatory Physiology, vol. 296, no. 6, pp. H2007-H2014, 2009.
B. Masri, B. Knibiehler and Y. Audigier. “Apelin signalling: Apromising pathway from cloning to pharmacology”. Cellular Signalling, vol. 17, pp. 415-426, 2005.
L. Li, G. Yang, Q. Li, Y. Tang, M. Yang, H. Yang and K. Li. “Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and Type 2 diabetic subjects”. Experimental and Clinical Endocrinology Diabetes, vol.114, pp. 544-548, 2006.
J. Boucher, B. Masri, D. Daviaud, S. Gesta, C. Guigné, A. Mazzucotelli, I. Castan-Laurell, I. Tack, B. Knibiehler, C. Carpéné, Y. Audigier, J. S. Saulnier-Blache and P. Valet. “Apelin, a newly identified adipokine up-regulated by insulin and obesity”. Endocrinology, vol. 146, pp. 1764-1771, 2005.
K. Polak, A. Czyzyk, T. Simoncini and B. Meczekalski. “New markers of insulin resistance in polycystic ovary syndrome”. Journal Endocrinology Invest, vol. 40, no. 1, pp. 1-8, 2017.
M. Irani, D.B. Seifer, R. V. Grazi, N. Julka, D. Bhatt, B. Kalgi, S. Irani, O. Tal, G. Lambert-Messerlian and R. Tal. “Vitamin D supplementation decreases TGF-β1 bioavailability in PCOS: A randomized placebo-controlled trial”. The Journal Clinical Endocrinology Metabolism, vol. 100, no. 11, pp. 4307-4314, 2015.
N. M. Rashad, A. I. Amin, A. E. Ali and M. H. Soliman. “Influence of obesity on soluble endoglin and transforming growth factorb1 in women with polycystic ovary syndrome”. Middle East Fertility Society Journal, vol. 23, pp. 418-424, 2018.
R. Tal, D. B. Seifer, A. Shohat-Tal, R.V. Grazi and H. E. Malter. ransforming growth factor-β1 and its receptor soluble endoglin are altered in polycystic ovary syndrome during controlled ovarian stimulation”. Fertility Sterility, 100, no. 2, pp. 538-543, 2013.
M. Olszanecka-Glinianowicz, P. Madej, M. Nylec, A. Owczarek, W. Szanecki, P. Skałba and J. Chudek. “Circulating apelin level in relation to nutritional status in polycystic ovary syndrome and its association with metabolic and hormonal disturbances”. Clinical Endocrinology (Oxford), vol. 79, no. 2, pp. 238-242, 2013.
S. Ö. Altinkaya, S. Nergiz, M. Küçük and H. Yüksel. “Apelin levels in relation with hormonal and metabolic profile in patients with polycystic ovary syndrome”. European Journal Obstetrics and Gynecology Reproductive Biology, vol. 176, pp. 168-672, 2014.
X. Sun, X. Wu, Y. Zhou, X. Yu and W. Zhang. “Evaluation of apelin and insulin resistance in patients with PCOS and therapeutic
effect of drospirenone-ethinylestradiol plus metformin. Medical Science Monitor, vol. 21, pp. 2547-2552, 2015.
C. K. Nath, B. Barman, A. Das, P. Rajkhowa, P. Baruah, M. Baruah and A. Baruah. “Prolactin and thyroid stimulating hormone affecting the pattern of LH/FSH secretion in patients with polycystic ovary syndrome: A hospital-based study from North East India”. Journal Family Medicine and Primary Care, vol. 8, no. 1, pp. 256-260, 2019.
B. Wiweko, I. Indra, C. Susanto, M. Natadisastra andA. Hestiantoro. “The correlation between serum AMH and HOMA-IR among PCOS phenotypes”. BMC Research Notes, vol. 11, no. 1, pp. 114, 2018.
K. Gören, N. Sağsöz, V. Noyan, A. Yücel, O. Cağlayan and M. S. Bostancı. “Plasma apelin levels in patients with polycystic ovary syndrome”. Journal of the Turkish German Gynecological Association, vol. 13, no. 1, pp. 27-31, 2012.
Copyright (c) 2020 Noor Alhuda K. Ibrahim, Wasnaa J. Mohammad, Sanan T. Abdawahab
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors who publish with this journal agree to the following terms:
1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License [CC BY-NC-ND 4.0] that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).